Massaro Ilaria, Rossi Oliviero, Incorvaia Cristoforo, Lombardi Carlo
Cell Therapy and Transfusion Medicine, Azienda Ospedaliero Universitaria Careggi, Florence, Largo Brambilla 1, 50134 Florence, Italy.
Allergy Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Florence, Italy.
Clin Mol Allergy. 2017 Aug 15;15:15. doi: 10.1186/s12948-017-0071-6. eCollection 2017.
Sublingual immunotherapy (SLIT) is a feasible option to classical subcutaneous immunotherapy to treat respiratory allergy and is increasingly prescribed in Europe. However, the lack of reimbursement may limit its prescription. In 2015, the 5-grass pollen tablets was authorized by the European Medicine Agency to treat grass-pollen induced rhinitis and was approved in Italy for full reimbursement. We evaluated the opinions of allergy specialists after the availability of the reimbursed 5-grass pollen tablets.
A multiple choice questionnaire composed by six questions was used to assess the specialists opinion. The questionnaire was uploaded on the free access online platform SurveyMonkey. The link to access the platform was sent to all members of the Società Italiana di Asma, Allergologia e Immunologia Clinica (SIAAIC). The access to the questionnaire was anonymous. At survey ending, the access was closed and data were downloaded directly from SurveyMonkey website.
The questionnaire was filled by 70 allergists. The majority of allergists felt as most important the concept of SLIT as a drug, the content of allergen extract mirroring the natural exposure, the pre-coseasonal schedule as the most patient's oriented, the very good profile of tolerability and safety, the importance of the build-up phase, and the importance of checking the patient after starting immunotherapy.
The opinions of the Italian allergy specialists about the reimbursed 5-grass-pollen tablets are very positive and make likely an appropriate prescription of SLIT for grass-pollen induced rhinitis in the next years.
舌下免疫疗法（SLIT）是治疗呼吸道过敏的一种可行的替代传统皮下免疫疗法的方法，在欧洲的处方量日益增加。然而，缺乏报销可能会限制其处方量。2015年，5种草花粉片被欧洲药品管理局批准用于治疗草花粉引起的鼻炎，并在意大利获得全额报销批准。我们评估了可报销的5种草花粉片上市后过敏专科医生的意见。
使用一份由六个问题组成的多项选择题问卷来评估专家意见。问卷上传至免费在线平台SurveyMonkey。访问该平台的链接发送给了意大利哮喘、变态反应与临床免疫学学会（SIAAIC）的所有成员。访问问卷是匿名的。调查结束时，访问关闭，数据直接从SurveyMonkey网站下载。
70名过敏症专科医生填写了问卷。大多数过敏症专科医生认为SLIT作为一种药物的概念、过敏原提取物的含量反映自然暴露情况、季前给药方案最以患者为导向、耐受性和安全性非常好、递增期的重要性以及开始免疫治疗后检查患者的重要性最为重要。
意大利过敏症专科医生对可报销的5种草花粉片的意见非常积极，这可能会使未来几年SLIT在治疗草花粉引起的鼻炎方面得到合理应用。
